Get the Stockscreener App
1.81
9.04%
0.15
X T L Biopharmaceuticals Ltd Adr stock is traded at $1.81, with a volume of 5,688.
It is up +9.04% in the last 24 hours and up +25.69% over the past month.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
See More
Previous Close:
$1.66
Open:
$1.7
24h Volume:
5,688
Relative Volume:
0.13
Market Cap:
$15.95M
Revenue:
-
Net Income/Loss:
$-2.25M
P/E Ratio:
-4.525
EPS:
-0.4
Net Cash Flow:
-
1W Performance:
-2.69%
1M Performance:
+25.69%
6M Performance:
-29.57%
1Y Performance:
+115.48%
1-Day Range:
$1.70
$1.82
1-Week Range:
$1.6553
$1.85
52-Week Range:
$0.7681
$4.9897
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Company Profile
Name
X T L Biopharmaceuticals Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare XTLB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XTLB
X T L Biopharmaceuticals Ltd Adr
|
1.81 | 15.95M | 0 | -2.25M | 0 | -0.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-15 | Initiated | H.C. Wainwright | Buy |
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Latest News
XTL Biopharmaceuticals Expands Portfolio with Social Proxy Acquisition Amidst Regional Challenges - TipRanks
XTL Biopharmaceuticals Adjusts Shares, Eyes Expansion - TipRanks
XTL Biopharmaceuticals Resolves Dispute with Social Proxy - TipRanks
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.03% - MSN
XTL Biopharmaceuticals Faces Financial Dispute After Acquisition - TipRanks
XTL Biopharmaceuticals Expands with AI Company Acquisition - TipRanks
XTL Biopharmaceuticals Announces Shareholder Meeting Outcomes - TipRanks
XTL Biopharmaceuticals Acquires The Social Proxy - TipRanks
Crude Oil Dips 2%; Signet Jewelers Shares Spike Higher - Markets Insider
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection - Yahoo Finance
The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon - Yahoo Finance
Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings - Yahoo Finance
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):